Table 1 Patient demographics and baseline characteristics (ITT population): post-hoc analysis
Ambrisentan | ||
|---|---|---|
CTD-PAH (N = 71) | IPAH/HPAH (N = 50) | |
Age (years), median (IQR) | 40 (19–59) | 40.6 (30–47) |
Women, n (%) | 69 (97.2) | 36 (72.0) |
Men | 2 (2.8) | 14 (28.0) |
CTD medications, n (%) | ||
Hydroxychloroquine | 29 (40.8) | – |
Glucocorticoids | 51 (71.8) | – |
Immunosuppressants | 27 (38.0) | – |
BMI, kg/m2 | 21.2 (3.2) | 22.2 (3.2) |
6MWT, m | 366.4 (60.4) | 397.3 (48.1) |
BDI score, n (%) | 2.7 (1.3) | 2.3 (1.5) |
Class II | 32 (45.1) | 31 (62.0) |
Class III | 39 (54.9) | 19 (38.0) |
NT-ProBNP, ng/L | 1837.5 (2209.6) | 1281.3 (1140.6) |
History of cardiovascular risk factors, n (%) | 3 (4.2) | 0 |